Recent News

• 11.07.2025 - Miricorilant, a Selective Glucocorticoid Receptor Modulator, Reprograms Hepatic Gene Networks in Metabolic Dysfunction–Associated Steatohepatitis
• 10.19.2025 - ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor
• 10.18.2025 - BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers
• 10.09.2025 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis

Recent Filings

• 11.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - 144 Report of proposed sale of securities
• 11.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2025 - EX-99.1 EX-99.1
• 11.04.2025 - 8-K Current report
• 11.03.2025 - 144 Report of proposed sale of securities
• 11.03.2025 - 144 Report of proposed sale of securities